Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
United States Legal Issues Regulation

Teva To Hand Florida $6.73m Over Price-Fixing Allegations

The Israeli Firm’s Largest State Price-Fixing Settlement Sum To Date

  • News

Executive Summary

Teva has agreed to settle Florida’s price-fixing allegations for $6.73m, its fifth and largest state settlement sum so far. Payouts to further states are expected.

You may also be interested in...



Five Things Facing Teva’s New CEO Richard Francis

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Teva Agrees $931,000 For Arkansas To Dismiss Price-Fixing Claims

Teva will pay $931, 000 to dismiss price-fixing claims filed in a 2020 multistate lawsuit but its legal troubles are far from over.  

Gloomy First Half Results For Mayne

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

Table

View full table

Topics

Tags:
United States Legal Issues Regulation
Latest Headlines

Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

UAE’s Bioventure Is Looking For Partners To Expand

Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?

See All
UsernamePublicRestriction

Register

GB152540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By